Clinical aspects of inflammation in Alzheimer's disease
- 1 January 2005
- journal article
- review article
- Published by Taylor & Francis in International Review of Psychiatry
- Vol. 17 (6) , 503-514
Abstract
In Alzheimer's disease (AD) there is increasing evidence that neurotoxicity is mediated by CNS inflammatory processes. These processes involve activation of microglia by amyloid-β leading to release of pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α among others. Neurotoxic processes mediated by these cytokines may include direct neuronal death by enhancement of apoptosis, decreased synaptic function as evidence by inhibition of long-term potentiation, and inhibition of hippocampal neurogenesis. Central nervous system (CNS) inflammation may predate the development of senile plaques and neurofibrillary tangles in AD and may prove to be a more sensitive marker of prodromal AD. New developments in measuring CNS inflammation include measuring cytokine release by peripheral blood mononuclear cells and the development of PET markers of microglial activation. There is epidemiological evidence that circulating serum IL-6 is associated with poorer cognition. While epidemiological studies suggest a protective effect of NSAIDs against development of AD, controlled trials of NSAIDs to date have not shown any protective effect of drug. New anti-inflammatory agents for treating or preventing AD may include novel NSAIDs and opioid antagonists. These developments provide an alternative or potential adjunct to anti-amyloid therapies for AD.Keywords
This publication has 109 references indexed in Scilit:
- Reduced β-Amyloid Production and Increased Inflammatory Responses in Presenilin Conditional Knock-out MiceJournal of Biological Chemistry, 2004
- Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta‐analysis of individual patient data from randomised controlled trialsInternational Journal of Geriatric Psychiatry, 2004
- Alzheimer Patients Treated With an AchE Inhibitor Show Higher IL-4 and Lower IL-1β Levels and Expression in Peripheral Blood Mononuclear CellsJournal of Clinical Psychopharmacology, 2004
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐BAnnals of Neurology, 2004
- Galantamine Provides Sustained Benefits in Patients with ‘Advanced Moderate’ Alzheimer’s Disease for at Least 12 MonthsDementia and Geriatric Cognitive Disorders, 2003
- Early inflammation and dementia: A 25‐year follow‐up of the Honolulu‐Asia aging studyAnnals of Neurology, 2002
- Double placebo design in a prevention trial for Alzheimer's diseaseControlled Clinical Trials, 2002
- Central β‐amyloid peptide‐induced peripheral interleukin‐6 responses in miceJournal of Neurochemistry, 2001
- Patterns of Brain Activation in People at Risk for Alzheimer's DiseaseNew England Journal of Medicine, 2000
- Tumor necrosis factor alters synaptic transmission in rat hippocampal slicesNeuroscience Letters, 1992